Skin Cancer & Melanoma

Latest News

Combination therapy with nivolumab and relatlimab produces superior progression-free survival vs nivolumab monotherapy among those with advanced melanoma in the phase 3 RELATIVITY-047 trial.
Nivolumab Combo Yields Sustained Benefit in Advanced Melanoma

June 7th 2023

Combination therapy with nivolumab and relatlimab produces superior progression-free survival vs nivolumab monotherapy among those with advanced melanoma in the phase 3 RELATIVITY-047 trial.

mRNA-4157 plus pembrolizumab appears well tolerated without an increase in immune-mediated adverse effects vs pembrolizumab monotherapy among those with high-risk melanoma in the phase 2 KEYNOTE-942 trial.
mRNA Vaccine/Pembrolizumab Reduces Metastasis/Death Risk in Melanoma

June 7th 2023

Targeting apoptosis in BRAF V600-mutated melanoma may be considered for future exploration in the post immunotherapy setting, according to an expert at Moffitt Cancer Center.
Dabrafenib Combo Shows Complete Responses in BRAF V600+ Metastatic Melanoma

June 7th 2023

Fianlimab/Cemiplimab Yields Activity in Pretreated Metastatic Melanoma | Image Credit: © David A Litman - stock.adobe.com.
Fianlimab/Cemiplimab Yields Activity in Pretreated Metastatic Melanoma

June 6th 2023

Common treatment-emergent adverse effects among patients receiving PRT811 for uveal melanoma or advanced glioma include nausea and vomiting in a phase 1 study.
PRT811 Yields Early Anti-Tumor Activity in Uveal Melanoma/Advanced Glioma

June 5th 2023

More News